Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary - About
INSM 
Insmed Inc (INSM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/07/2025: INSM (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -25.01% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/07/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 14.67B USD | Price to earnings Ratio - | 1Y Target Price 95.08 |
Price to earnings Ratio - | 1Y Target Price 95.08 | ||
Volume (30-day avg) 1782395 | Beta 1.11 | 52 Weeks Range 21.92 - 84.91 | Updated Date 02/21/2025 |
52 Weeks Range 21.92 - 84.91 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.57 |
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-02-20 | When Before Market | Estimate -1.23 | Actual -1.32 |
Profitability
Profit Margin -251.24% | Operating Margin (TTM) -234.79% |
Management Effectiveness
Return on Assets (TTM) -29.31% | Return on Equity (TTM) -890.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14848406653 | Price to Sales(TTM) 40.34 |
Enterprise Value 14848406653 | Price to Sales(TTM) 40.34 | ||
Enterprise Value to Revenue 40.83 | Enterprise Value to EBITDA -6.05 | Shares Outstanding 180999008 | Shares Floating 164639176 |
Shares Outstanding 180999008 | Shares Floating 164639176 | ||
Percent Insiders 1.21 | Percent Institutions 113.74 |
AI Summary
Insmed Inc. (INS): A Comprehensive Overview
Company Profile:
Detailed History and Background:
- Founded: 2007.
- Headquarters: Bridgewater, New Jersey.
- Focus: Rare disease therapeutics.
- Milestones:
- 2008: Public offering.
- 2018: Received FDA approval for Arikayce, its first commercial product.
- 2021: Launched Brensocatib.
- Company Structure: Led by CEO Will Lewis, Board of Directors oversees operations.
Core Business Areas:
- Developing and commercializing innovative therapies for rare, severe diseases.
- Current focus: Neuromuscular and other serious medical conditions.
Products and Market Share:
Top Products:
- Arikayce: Treats nontuberculous mycobacterial (NTM) lung disease.
- Market share: NTM market is estimated at $1.2 billion.
- Competitors: Insmed holds a significant market share in this space.
- Brensocatib: Treats aromatic L-amino acid decarboxylase (AADC) deficiency.
- Market share: AADC deficiency market is estimated at $500 million.
- Competitors: Market is less saturated, offering significant potential.
Financial Performance:
- Recent financials (2022): Revenue – $278.4 million, Net income – ($249.8 million), EPS – ($4.57).
- YoY comparison: Revenue increased 88%, losses decreased from previous year.
- Balance sheet and cash flow: Strong cash position and positive operating cash flow.
Dividends and Shareholder Returns:
- Dividend history: No dividend payments yet.
- Shareholder returns: Negative over past 1 year, positive over 5 and 10 year periods.
Growth Trajectory:
- Historical growth: Revenue has grown significantly in recent years.
- Future growth: Company forecasts continued revenue growth, driven by Arikayce and Brensocatib.
- Recent initiatives: Expansion into international markets and development pipeline expansion.
Market Dynamics:
- Industry trends: Growing demand for rare disease treatments.
- Company position: Insmed is well-positioned in this market due to its innovative products.
Competitors:
- Arikayce: Chimerix (CMRX), Paratek Pharmaceuticals (PRTK).
- Brensocatib: No direct competitors, offering a unique market opportunity.
Challenges and Opportunities:
Challenges:
- Competition in the NTM market.
- Brensocatib's market adoption and reimbursement challenges.
Opportunities:
- Expanding Arikayce international reach.
- New product launches for AADC deficiency and other rare diseases.
Recent Acquisitions (last 3 years):
- None.
AI-Based Fundamental Rating:
- Rating: 6.5/10.
- Justification: Strong financial health, unique market position, and future growth potential. However, concerns regarding profitability and competition exist.
Sources:
- Insmed Inc. Investor Relations: https://investors.insmed.com/
- SEC filings: https://www.sec.gov/edgar/search/#/company?cik=1323546
- Statista: https://www.statista.com/
Disclaimer: This information is for informational purposes only and should not be considered financial advice.
Please note: This information is accurate as of November 14, 2023. I do not have access to information beyond this date.
About Insmed Inc
Exchange NASDAQ | Headquaters Bridgewater, NJ, United States | ||
IPO Launch date 2000-06-01 | President, CEO & Chairman Mr. William H. Lewis J.D., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.insmed.com |
Full time employees - | Website https://www.insmed.com | ||
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.